Home/ Stocks/ TLSI

TriSalus Life Sciences, Inc. Common Stock

TLSI XNAS

$5.61 +0.74 (+15.20%) ▲ 15-min delayed

Open

$4.94

High

$5.76

Low

$4.67

Volume

700.8K

Market Cap

$299.10M

About TriSalus Life Sciences, Inc. Common Stock

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Sector: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS Employees: 102 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$8.90M	$1.54M	$0.03
FY 2025	$45.15M	$-39,227,000	$-1.84
Q3 2025	$11.57M	$-10,811,000	$-0.96
Q2 2025	$11.21M	$-8,288,000	$-0.27

Related Market News

No specific coverage for TLSI yet. Check out our latest market news or earnings calendar.

Get TLSI Alerts

Stay ahead with breaking news, price alerts, and expert analysis on TriSalus Life Sciences, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.